These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8446804)

  • 1. The succession procedure for interim analysis: extensions for early acceptance of Ho and for flexible times of analysis.
    Falissard B; Lellouch J
    Stat Med; 1993 Jan; 12(1):51-67. PubMed ID: 8446804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some extensions to a new approach for interim analysis in clinical trials.
    Falissard B; Lellouch J
    Stat Med; 1991 Jun; 10(6):949-55; discussion 956-7. PubMed ID: 1876784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim analysis: the alpha spending function approach.
    DeMets DL; Lan KK
    Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a continuous stopping boundary from an alpha spending function.
    Betensky RA
    Biometrics; 1998 Sep; 54(3):1061-71. PubMed ID: 9750252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the choice of times for data analysis in group sequential clinical trials.
    Li ZH; Geller NL
    Biometrics; 1991 Jun; 47(2):745-50. PubMed ID: 1912268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of carcinoma of the respiratory and digestive tracts with vindesine sulfate. Phase II clinical trial].
    Domenge C; Richard JM
    Ann Otolaryngol Chir Cervicofac; 1984; 101(2):119-21. PubMed ID: 6372615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computations for group sequential boundaries using the Lan-DeMets spending function method.
    Reboussin DM; DeMets DL; Kim KM; Lan KK
    Control Clin Trials; 2000 Jun; 21(3):190-207. PubMed ID: 10822118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-designing trial combined with classical group sequential monitoring.
    Yin G; Shen Y
    J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unified method for monitoring and analysing controlled trials.
    Grossman J; Parmar MK; Spiegelhalter DJ; Freedman LS
    Stat Med; 1994 Sep; 13(18):1815-26. PubMed ID: 7997715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of carcinoma of the upper respiratory and digestive tract].
    Cachin Y; Domenge C
    Rev Laryngol Otol Rhinol (Bord); 1986; 107(1):5-7. PubMed ID: 3715237
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A general formulation for a one-sided group sequential design.
    Moser BK; George SL
    Clin Trials; 2005; 2(6):519-28. PubMed ID: 16422312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group sequential designs using a family of type I error probability spending functions.
    Hwang IK; Shih WJ; De Cani JS
    Stat Med; 1990 Dec; 9(12):1439-45. PubMed ID: 2281231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of chemotherapy in 366 cases of cancers of the upper respiratory and digestive tracts].
    Meeus-Bith L; Mahé E
    Rev Laryngol Otol Rhinol (Bord); 1980; 101(5-6):229-33. PubMed ID: 7444237
    [No Abstract]   [Full Text] [Related]  

  • 19. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of cisplatin with 5-fluorouracil in the primary treatment of advanced carcinoma of the upper respiratory and digestive tract].
    Joveniaux A; Caty A; Adenis L
    Bull Cancer; 1984; 71(4):390. PubMed ID: 6541953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.